12h
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell (“CAR-T”) therapy product candidate, TPST ...
TGE TV on MSN
Meet the fastest and most expensive Audi R8 ever
This is the fastest and most expensive Audi R8 ever built and it takes performance to another level.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results